SAB BIOTHERAPEUTICS INC (SABS) Forecast, Price Target & Analyst Ratings
NASDAQ:SABS • US78397T2024
3.7701 USD
-0.16 (-4.07%)
Last: Mar 5, 2026, 02:09 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SAB BIOTHERAPEUTICS INC (SABS).
Forecast Snapshot
Consensus Price Target
$9.56
+ 153.64% Upside
Next Earnings Forecast
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$0.20
Revenue Estimate
ChartMill Buy Consensus
85.71%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$9.56
Upside
+ 153.64%
From current price of $3.77 to mean target of $9.56, Based on 14 analyst forecasts
Low
$5.05
Median
$8.16
High
$15.75
Price Target Revisions
1 Month
0.00%
3 Months
6.13%
Price Target Summary
14 analysts have analysed SABS and the average price target is 9.56 USD. This implies a price increase of 153.64% is expected in the next year compared to the current price of 3.7701.
The average price target has been revised upward by 6.13% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.71%
SABS was analyzed by 14 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about SABS.
In the previous month the buy percentage consensus was at a similar level.
SABS was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-07 | UBS | Initiate | Buy |
| 2025-12-19 | Guggenheim | Initiate | Buy |
| 2025-12-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-17 | Leerink Partners | Initiate | Outperform |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-29 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-01-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-09 | Craig-Hallum | Initiate | Buy |
| 2024-09-12 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-09-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-28 | Oppenheimer | Initiate | Outperform |
| 2024-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-07 | Brookline Capital | Initiate | Buy |
| 2024-05-21 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$0.20
Revenue Estimate
Revenue Q2Q-100.00%
EPS Q2Q83.46%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-7.02%
EPS (3 Months)
38.28%
Next Earnings Summary
SABS is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -0.2 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 23.904M -60.73% | 2.239M -90.63% | 1.322M -40.94% | -100.00% | 578.003K | 7.283M 1,160.03% | 79.48M 991.31% | 247.02M 210.80% | 376.72M 52.51% | 598.4M 58.84% | 810.9M 35.51% | ||
| EBITDA YoY % growth | -25.627M -115.26% | -34.322M -33.93% | -38.018M -10.77% | -47.287M -24.38% | -77.204M -63.27% | -93.585M -21.22% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.796M -114.99% | -37.975M -31.88% | -42.811M -12.73% | -47.307M -10.50% | -65.461M -38.37% | -83.471M -27.51% | -85.978M -3.00% | -109.908M -27.83% | -45.898M 58.24% | -24.123M 47.44% | 133.16M 652.00% | 273.36M 105.29% | |
| Operating Margin | -120.47% | -1,696.07% | -3,237.33% | N/A | N/A | -14,441.29% | -1,180.53% | -138.28% | -18.58% | -6.40% | 22.25% | 33.71% | |
| EPS YoY % growth | -2.70 -37.51% | -7.28 -169.63% | -3.74 48.68% | -0.46 87.71% | -0.62 -35.56% | -0.48 22.95% | -0.39 19.15% | -0.29 26.32% | 0.64 325.00% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 83.46% | -0.19 65.39% | -0.18 83.47% | -0.18 -17.86% | -0.16 19.50% | -0.06 68.42% | -0.07 60.38% | -0.06 65.38% | -0.06 62.50% |
| Revenue Q2Q % growth | -100.00% | ||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -13.651M -36.39% | -14.477M -35.22% | -15.586M -61.22% | -16.575M -31.39% | -17.666M -29.42% | -16.065M -10.97% | -16.83M -7.98% | -17.595M -6.15% | -18.36M -3.93% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
23.24%
EPS Next 5 Year
13.98%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-24.65%
Revenue Next 5 Year
125.90%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-27.39%
EBIT Next 5 Year
N/A
SAB BIOTHERAPEUTICS INC / SABS Forecast FAQ
What do analysts expect the price target to be for SAB BIOTHERAPEUTICS INC (SABS)?
14 analysts have analysed SABS and the average price target is 9.56 USD. This implies a price increase of 153.64% is expected in the next year compared to the current price of 3.7701.
What is the next earnings date for SABS stock?
SAB BIOTHERAPEUTICS INC (SABS) will report earnings on 2026-03-30, after the market close.
What are the consensus estimates for SABS stock next earnings?
The consensus EPS estimate for the next earnings of SAB BIOTHERAPEUTICS INC (SABS) is -0.2 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for SABS stock?
The consensus rating for SAB BIOTHERAPEUTICS INC (SABS) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.